183 related articles for article (PubMed ID: 29704172)
21. Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and Dissolved by Direct Factor Xa Inhibitor.
Higashi E; Hatano T; Ando M; Chihara H; Ogura T; Suzuki K; Yamagami K; Kondo D; Kamata T; Sakai S; Sakamoto H; Nagata I
World Neurosurg; 2019 Nov; 131():209-212. PubMed ID: 31442658
[TBL] [Abstract][Full Text] [Related]
22. Adenosine A₂B receptor agonism inhibits neointimal lesion development after arterial injury in apolipoprotein E-deficient mice.
Bot I; de Vries H; Korporaal SJ; Foks AC; Bot M; van Veldhoven J; Ter Borg MN; van Santbrink PJ; van Berkel TJ; Kuiper J; Ijzerman AP
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2197-205. PubMed ID: 22743060
[TBL] [Abstract][Full Text] [Related]
23. Cholesterol Crystal Embolism Induced by Direct Factor Xa Inhibitor: A First Case Report.
Oka H; Kamimura T; Hiramatsu Y; Fukumitsu K; Iwata R; Kondo M; Hirashima Y; Aihara S; Harada A; Tsuruya K
Intern Med; 2018 Jan; 57(1):71-74. PubMed ID: 28943551
[TBL] [Abstract][Full Text] [Related]
24. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619
[TBL] [Abstract][Full Text] [Related]
25. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
26. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
27. Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice.
Iwatsuki Y; Kawasaki T; Hayashi K; Moritani Y; Nii T; Miyata K
Thromb Haemost; 2004 Dec; 92(6):1221-8. PubMed ID: 15583727
[TBL] [Abstract][Full Text] [Related]
28. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
[TBL] [Abstract][Full Text] [Related]
29. Both apolipoprotein E and immune deficiency exacerbate neointimal hyperplasia after vascular injury in mice.
Zhu B; Reardon CA; Getz GS; Hui DY
Arterioscler Thromb Vasc Biol; 2002 Mar; 22(3):450-5. PubMed ID: 11884289
[TBL] [Abstract][Full Text] [Related]
30. Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2-ERK 1/2 pathway.
Maeda K; Kuriyama N; Noguchi D; Ito T; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Murata Y; Tanemura A; Kishiwada M; Mizuno S
PLoS One; 2024; 19(5):e0292628. PubMed ID: 38748746
[TBL] [Abstract][Full Text] [Related]
31. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of neointimal hyperplasia by a specific thrombin inhibitor.
Wahlgren CM; Frebelius S; Swedenborg J
Scand Cardiovasc J; 2004 Mar; 38(1):16-21. PubMed ID: 15204242
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Meddahi S; Samama MM
J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
[TBL] [Abstract][Full Text] [Related]
34. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
[TBL] [Abstract][Full Text] [Related]
35. Osthole inhibits intimal hyperplasia by regulating the NF-κB and TGF-β1/Smad2 signalling pathways in the rat carotid artery after balloon injury.
Li YQ; Wang JY; Qian ZQ; Li YL; Li WN; Gao Y; Yang DL
Eur J Pharmacol; 2017 Sep; 811():232-239. PubMed ID: 28648404
[TBL] [Abstract][Full Text] [Related]
36. Deficiency of Long Pentraxin PTX3 Promoted Neointimal Hyperplasia after Vascular Injury.
Ishino M; Shishido T; Suzuki S; Katoh S; Sasaki T; Funayama A; Netsu S; Hasegawa H; Honda S; Takahashi H; Arimoto T; Miyashita T; Miyamoto T; Watanabe T; Takeishi Y; Kubota I
J Atheroscler Thromb; 2015; 22(4):372-8. PubMed ID: 25342475
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide inhibits neointimal hyperplasia following vascular injury via differential, cell-specific modulation of SOD-1 in the arterial wall.
Bahnson ES; Koo N; Cantu-Medellin N; Tsui AY; Havelka GE; Vercammen JM; Jiang Q; Kelley EE; Kibbe MR
Nitric Oxide; 2015 Jan; 44():8-17. PubMed ID: 25460325
[TBL] [Abstract][Full Text] [Related]
38. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
[TBL] [Abstract][Full Text] [Related]
39. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression.
Xu Y; Zhou S; Fang Z; Li X; Huang D; Liu Q; Zheng C
Pharm Biol; 2014 Sep; 52(9):1196-203. PubMed ID: 25116077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
